Hem › Lungcancer › Kalifornien › San Francisco
Kliniska studier för Lungcancer i San Francisco, CA
22 studier för Lungcancer söker deltagare vid platser i och runt San Francisco (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
A Study of ZW251 in Participants With Advanced Solid Tumors
RekryterarFas 1
- UCSF Comprehensive Cancer Center, San Francisco
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RekryterarFas 3
- California Pacific Medical Center-Pacific Campus, San Francisco
- Kaiser Permanente-San Francisco, San Francisco
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
RekryterarFas 3
- Kaiser Permanente-San Francisco, San Francisco
Smoking Cessation CM for Veterans With or at Risk for Cancer
RekryterarFriska volontärer välkomna
- San Francisco VA Medical Center, San Francisco, CA, San Francisco
Distance-Based Exercise to Preserve Function and Prevent Disability
Rekryterar
- Kaiser Permanente-San Francisco, San Francisco
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RekryterarFas 3
- Kaiser Permanente-San Francisco, San Francisco
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
RekryterarFas 3
- San Francisco Oncology Associates ( Site 0066), San Francisco
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
RekryterarFas 1/2
- University of California, San Francisco (UCSF), San Francisco
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RekryterarFas 3
- California Pacific Medical Center, San Francisco
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
RekryterarFas 1
- University of California San Francisco, San Francisco
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
RekryterarFas 3
- UCSF Medical Center-Mission Bay, San Francisco
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
RekryterarFas 3
- California Pacific Medical Center-Pacific Campus, San Francisco
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
RekryterarFas 2
- University of California San Francisco, San Francisco
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
RekryterarFas 1/2
- UCSF Medical Center - Mission Bay, San Francisco
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RekryterarFas 2
- California Pacific Medical Center-Pacific Campus, San Francisco
- Kaiser Permanente-San Francisco, San Francisco
- Veterans Affairs Medical Center - San Francisco, San Francisco
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RekryterarFas 2/3
- Kaiser Permanente-San Francisco, San Francisco
- Veterans Affairs Medical Center - San Francisco, San Francisco
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RekryterarFas 2
- California Pacific Medical Center-Pacific Campus, San Francisco
- Kaiser Permanente-San Francisco, San Francisco
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Rekryterar
- Zuckerberg San Francisco General, San Francisco
- Kaiser Foundation Research Institute, San Francisco
- University of San Francisco, San Francisco
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RekryterarFas 1/2
- University of California at San Francisco, San Francisco
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
RekryterarFas 1/2
- University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, San Francisco
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
RekryterarFas 1
- University of California San Francisco, San Francisco
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekryterarObservationsstudie
- Massive Bio SYNERGY-AI site, San Francisco
Lungcancer-studier i andra städer
- Houston, TX78 studier
- Boston, MA62 studier
- New York City, NY60 studier
- Los Angeles, CA45 studier
- Arlington, VA41 studier
- Washington, DC41 studier
- Chicago, IL41 studier
- Baltimore, MD40 studier
- Nashville, TN40 studier
- St. Louis, MO39 studier
- Columbus, OH37 studier
- Philadelphia, PA36 studier
Andra studier i San Francisco
- Prostatacancer45 studier
- Bröstcancer43 studier
- Icke-småcellig lungcancer36 studier
- Cancer (alla typer)35 studier
- Hjärtsvikt29 studier
- Metastaserande cancer28 studier
- Melanom22 studier
- Bukspottkörtelcancer20 studier
- Äggstockscancer19 studier
- Kolorektal cancer18 studier
- Hjärt-kärlsjukdom18 studier
- Glioblastom17 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.